Abstract:BACKGROUND: Onychomycosis is one of the commonest dermatological diseases worldwide. The antifungal activity of current medications varies, and treatment failure occurs in 25-40% of treated patients.AIMS: To evaluate the in vitro antifungal activity of itraconazole, fluconazole, terbinafine and voriconazole against isolates taken from patients with onychomycosis.METHODS: Nail isolates were evaluated according to methods described in the protocols of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST) and the Clinical and Laboratory Standards Institute (CLS M38-A), and a CLSI M38-A modified technique for dermatophytes. Antifungal agents tested included terbinafine, itraconazole, voriconazole and fluconazole.RESULTS: In total, 103 isolates of Candida species (n = 58), Fusarium species (n = 10), Fusicoccum dimidiatum (n = 4), Scytalidium hyalinum (n = 1) and dermatophytes (n = 30) were evaluated. Itraconazole and voriconazole were the most active agents against Candida species, whereas terbinafine and voriconazole were most potent against dermatophytes. Fusarium species had the highest minimum inhibitory concentration (MIC) values with all antifungal agents.CONCLUSIONS: The aetiological agents of onychomycosis that we found differ from those found in other countries, suggesting that the heat and humidity of the Colombian climate could favour yeast nail infections. The lowest MICs for Candida species (obtained with voriconazole, followed by itraconazole) may be explained by emerging resistant strains. Against dermatophytes, the lowest MICs were obtained with terbinafine, followed by voriconazole. MIC values for the evaluated agents were higher for non-dermatophyte filamentous fungi than for other fungi. As MIC breakpoints have not yet been established for onychomycosis therapies, it remains unclear if in vitro activities of antifungal drugs are predictive of clinical outcome. Well-designed clinical studies are necessary to assist clinicians in choosing the best antifungal agents.

In Vitro Antifungal Activity of Micafungin and Caspofungin Against Dermatophytes Isolated from China

In Vitro Antifungal Activity of Caspofungin and Micafungin Against 8 Species of Dermatophyte

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

In vitro antifungal activity of micafungin against clinical strains of Candida spp. and Aspergillus spp. isolated from China

Antifungal Activity of Antifungal Drugs, as Well as Drug Combinations Against Exophiala dermatitidis

In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin Against Invasive Fungal Isolates (2017 to 2022) in China

In vitro activities of six antifungal agents and their combinations against Chaetomium spp.

In Vitro Activities of a Wide Panel of Antifungal Drugs against Various Scopulariopsis and Microascus Species

In Vitro Susceptibility Testing of 16 Strains of Exophiala Dermatitidis to 6 Commonly Used Antifungal Agents.

In Vitro Antifungal Activity of Tacrolimus Alone or in Combination with Itraconazole or Terbinafine Against Exophiala Dermatitidis

In vitro activity of fluconazole, itraconazole, voriconazole and terbinafine against fungi causing onychomycosis

In Vitro Susceptibility Testing of Aspergillus Spp. Against Voriconazole, Itraconazole, Posaconazole, Amphotericin B and Caspofungin

In vitro activities of nine antifungal agents against rare pathogenic fungi.

Comparison of In Vitro Antifungal Activities of Efinaconazole and Currently Available Antifungal Agents against a Variety of Pathogenic Fungi Associated with Onychomycosis

In Vitro Activity of Antifungal Drugs Against Trichophyton rubrum and Trichophyton mentagrophytes spp. by E-Test Method and Non-supplemented Mueller–Hinton Agar Plates

In Vitro Synergistic Antifungal Activities of Caspofungin in Combination with Fluconazole or Voriconazole Against Candida Species Determined by the Etest Method

Development of treatment strategies by comparing the minimum inhibitory concentrations and minimum fungicidal concentrations of azole drugs in dermatophytes

In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs

In Vitro Susceptibility Testing of Amorolfine in Pathogenic Fungi Isolated from Dermatomycosis Patients in China

In vitro susceptibility testing of eight antifungal agents against pathogenic fungi isolated from superficial mycoses

MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp